SLS— SELLAS Life Sciences Group, Inc.

MaterialsBiotechnology$2.2B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Research and development	$16.0M-16.1%	$19.1M-20.5%	$24.0M+18.4%	$20.3M
General and administrative	$12.3M-1.3%	$12.4M-10.4%	$13.9M+10.2%	$12.6M
Total operating expenses	$28.3M-10.3%	$31.5M-16.8%	$37.9M-11.8%	$43.0M
Loss from operations	-$28.3M+10.3%	-$31.5M+16.8%	-$37.9M+9.7%	-$42.0M
Interest income	$1.4M+123.3%	$632K+20.4%	$525K+65.6%	$317K
Total non-operating income	$1.4M+123.3%	$632K+19.5%	$529K-18.5%	$649K
Net loss	-$26.9M+13.0%	-$30.9M+17.3%	-$37.3M+9.6%	-$41.3M
Net loss per common share, basic (in dollars per share)	-$0.25+50.0%	-$0.50+62.7%	-$1.34+37.1%	-$2.13
Net loss per common share, diluted (in dollars per share)	-$0.25+50.0%	-$0.50+62.7%	-$1.34+37.1%	-$2.13
Weighted-average common shares outstanding, basic (in shares)	109.1M+78.2%	61.2M+120.3%	27.8M+43.2%	19.4M
Weighted-average common shares outstanding, diluted (in shares)	109.1M+78.2%	61.2M+120.3%	27.8M+43.2%	19.4M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.